

Silvia Martinelli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3763276/publications.pdf>

Version: 2024-02-01

40
papers

757
citations

516710

16
h-index

526287

27
g-index

40
all docs

40
docs citations

40
times ranked

1352
citing authors

#	ARTICLE	IF	CITATIONS
1	BTK Inhibitors Impair Platelet-Mediated Antifungal Activity. <i>Cells</i> , 2022, 11, 1003.	4.1	7
2	Indoleamine 2, 3-Dioxygenase 1 Mediates Survival Signals in Chronic Lymphocytic Leukemia via Kynurenine/Aryl Hydrocarbon Receptor-Mediated MCL1 Modulation. <i>Frontiers in Immunology</i> , 2022, 13, 832263.	4.8	6
3	IRF4 modulates the response to BCR activation in chronic lymphocytic leukemia regulating IKAROS and SYK. <i>Leukemia</i> , 2021, 35, 1330-1343.	7.2	13
4	A single-tube multiplex method for monitoring mutations in cysteine 481 of Bruton Tyrosine Kinase (BTK) gene in chronic lymphocytic leukemia patients treated with ibrutinib. <i>Leukemia and Lymphoma</i> , 2021, 62, 2018-2021.	1.3	2
5	Neoantigen-Specific T-Cell Immune Responses: The Paradigm of NPM1-Mutated Acute Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9159.	4.1	7
6	IRF4 L116R mutation promotes proliferation of chronic lymphocytic leukemia B cells inducing MYC. <i>Hematological Oncology</i> , 2021, 39, 707-711.	1.7	5
7	How to Improve Prognostication in Acute Myeloid Leukemia with CBFβ-MYH11 Fusion Transcript: Focus on the Role of Molecular Measurable Residual Disease (MRD) Monitoring. <i>Biomedicines</i> , 2021, 9, 953.	3.2	6
8	Multiparametric Flow Cytometry for MRD Monitoring in Hematologic Malignancies: Clinical Applications and New Challenges. <i>Cancers</i> , 2021, 13, 4582.	3.7	28
9	Pre-existing cytopenia heralding de novo acute myeloid leukemia: uncommon presentation of NPM1-mutated AML in a single-center study. <i>Leukemia Research</i> , 2021, 111, 106747.	0.8	0
10	Notch2 Increases the Resistance to Venetoclax-Induced Apoptosis in Chronic Lymphocytic Leukemia B Cells by Inducing Mcl-1. <i>Frontiers in Oncology</i> , 2021, 11, 777587.	2.8	9
11	Indoleamine 2,3-Dioxygenase Mediates Survival of Chronic Lymphocytic Leukemia B Cells through Aryl Hydrocarbon Receptor By Inducing Mcl1. <i>Blood</i> , 2020, 136, 19-19.	1.4	0
12	NOTCH2 Contributes to Venetoclax Resistance in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2019, 134, 4280-4280.	1.4	3
13	Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide. <i>Leukemia and Lymphoma</i> , 2018, 59, 423-433.	1.3	7
14	Angiopoietin-2 acts as a survival factor for chronic lymphocytic leukemia B cells throughout T cell receptor engagement. <i>Hematological Oncology</i> , 2018, 36, 372-375.	1.7	0
15	Idelalisib impairs T-cell-mediated immunity in chronic lymphocytic leukemia. <i>Haematologica</i> , 2018, 103, e598-e601.	3.5	16
16	The expression of endothelin-1 in chronic lymphocytic leukemia is controlled by epigenetic mechanisms and extracellular stimuli. <i>Leukemia Research</i> , 2017, 54, 17-24.	0.8	8
17	Macitentan, a double antagonist of endothelin receptors, efficiently impairs migration and microenvironmental survival signals in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2017, 8, 90013-90027.	1.8	5
18	Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2016, 7, 65968-65981.	1.8	84

#	ARTICLE	IF	CITATIONS
19	Lenalidomide in chronic lymphocytic leukemia: the present and future in the era of tyrosine kinase inhibitors. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 97, 291-302.	4.4	12
20	Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisib. <i>Journal of Hematology and Oncology</i> , 2015, 8, 60.	17.0	49
21	Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia. <i>Haematologica</i> , 2015, 100, 253-262.	3.5	40
22	Ibrutinib Targets Nurse-like Cells Supporting an Immunosuppressive Phenotype in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 613-613.	1.4	0
23	Endothelin-1 Promotes Survival and Chemoresistance in Chronic Lymphocytic Leukemia B Cells through ETA Receptor. <i>PLoS ONE</i> , 2014, 9, e98818.	2.5	33
24	Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia. <i>Experimental Hematology</i> , 2014, 42, 126-136.e1.	0.4	23
25	Lenalidomide Promotes a Pro-Inflammatory Switch of Nurse-like Cells Derived from Chronic Lymphocytic Leukemia. <i>Blood</i> , 2014, 124, 3286-3286.	1.4	0
26	The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation. <i>Haematologica</i> , 2013, 98, 1115-1123.	3.5	92
27	ANGPT2 promoter methylation is strongly associated with gene expression and prognosis in chronic lymphocytic leukemia. <i>Epigenetics</i> , 2013, 8, 720-729.	2.7	30
28	Clinical heterogeneity of <i>de novo</i> 11q deletion chronic lymphocytic leukaemia: prognostic relevance of extent of 11q deleted nuclei inside leukemic clone. <i>Hematological Oncology</i> , 2013, 31, 88-95.	1.7	25
29	Physical contact with endothelial cells through $\alpha 1$ - and $\alpha 2$ - integrins rescues chronic lymphocytic leukemia cells from spontaneous and drug-induced apoptosis and induces a peculiar gene expression profile in leukemic cells. <i>Haematologica</i> , 2012, 97, 952-960.	3.5	29
30	In Vitro and in Vivo Evidence of an Anti-Angiogenic Effect of Lenalidomide in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012, 120, 1782-1782.	1.4	2
31	Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia. <i>Blood</i> , 2010, 116, 584-592.	1.4	51
32	Increased angiogenesis induced by chronic lymphocytic leukemia B cells is mediated by leukemia-derived Ang2 and VEGF. <i>Leukemia Research</i> , 2010, 34, 312-321.	0.8	48
33	Interferon α may restore sensitivity to tyrosine kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation. <i>British Journal of Haematology</i> , 2009, 146, 227-230.	2.5	4
34	Angiopoietin-2 Plasma Dosage Predicts Time to First Treatment (TTFT) and Overall Survival (OS) in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2009, 114, 1260-1260.	1.4	0
35	Increased expression of angiopoietin-2 characterizes early B-cell chronic lymphocytic leukemia with poor prognosis. <i>Leukemia Research</i> , 2008, 32, 593-597.	0.8	22
36	Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor. <i>Haematologica</i> , 2008, 93, 1252-1255.	3.5	19

#	ARTICLE	IF	CITATIONS
37	Angiopoietin-2 expression in B-cell chronic lymphocytic leukemia: association with clinical outcome and immunoglobulin heavy-chain mutational status. <i>Leukemia</i> , 2007, 21, 1312-1315.	7.2	14
38	Gene expression profiling of acute promyelocytic leukaemia identifies two subtypes mainly associated with Flt3 mutational status. <i>Leukemia</i> , 2006, 20, 103-114.	7.2	42
39	Angiopoietin-2 Expression in B-Cell Chronic Lymphocytic Leukemia: Association with Clinical Outcome and Immunoglobulin Heavy-Chain Mutational Status.. <i>Blood</i> , 2006, 108, 2780-2780.	1.4	4
40	Immunoglobulin Mutational Status Detected through Single-Round Amplification of Partial VH Region Represents a Good Prognostic Marker for Clinical Outcome in Chronic Lymphocytic Leukemia. <i>Journal of Molecular Diagnostics</i> , 2005, 7, 566-574.	2.8	12